Eupraxia Pharmaceuticals (NASDAQ:EPRX) Rating Increased to Strong-Buy at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) to a strong-buy rating in a report issued on Thursday,Zacks.com reports.

Separately, Rodman & Renshaw began coverage on Eupraxia Pharmaceuticals in a research report on Thursday. They issued a “buy” rating and a $9.00 price target for the company.

Eupraxia Pharmaceuticals Price Performance

NASDAQ:EPRX opened at $3.13 on Thursday. The firm has a market capitalization of $85.41 million and a price-to-earnings ratio of -4.35. The business has a 50 day simple moving average of $2.67 and a 200-day simple moving average of $2.68. Eupraxia Pharmaceuticals has a 1 year low of $2.20 and a 1 year high of $5.58.

Institutional Trading of Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new stake in shares of Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 13,000 shares of the company’s stock, valued at approximately $34,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.